Health‐related quality‐of‐life scales in Parkinson's disease: Critique and recommendations
Identifieur interne : 000264 ( Main/Corpus ); précédent : 000263; suivant : 000265Health‐related quality‐of‐life scales in Parkinson's disease: Critique and recommendations
Auteurs : Pablo Martinez-Martin ; Martine Jeukens-Visser ; Kelly E. Lyons ; C. Rodriguez-Blazquez ; Caroline Selai ; Andrew Siderowf ; Mickie Welsh ; Werner Poewe ; Oliver Rascol ; Cristina Sampaio ; Glenn T. Stebbins ; Christopher G. Goetz ; Anette SchragSource :
- Movement Disorders [ 0885-3185 ] ; 2011-11.
English descriptors
- KwdEn :
Abstract
Health‐related quality of life is an important patient‐reported outcome used in intervention trials and for monitoring the consequences of health status on physical, mental, and social domains. Parkinson's disease is a complex disorder that strongly affects patients' quality of life. Several health‐related quality of life tools have been used in Parkinson's disease. A Movement Disorder Society Task Force was commissioned to rate the psychometric quality of available health‐related quality of life scales as applied to Parkinson's disease. Following the methodology adopted by previous work of the Movement Disorder Society Task Force, a review of generic and specific health‐related quality of life scales applied in studies on Parkinson's disease was completed. Considering the scales from 3 perspectives—use in Parkinson's disease, use by multiple research groups, and clinimetric properties—a final classification as “recommended,” “suggested,” or “listed” was applied to each reviewed instrument. Four generic scales (EuroQoL, Nottingham Health Profile, 36‐Item Short‐Form Health Survey, and Sickness Impact Profile) and 5 specific scales (39‐Item Parkinson's Disease Questionnaire, Parkinson's Disease Questionnaire Short Form, Parkinson's Disease Quality of Life Questionnaire, Parkinson's Impact Scale, and Scales for Outcomes in Parkinson's Disease–Psychosocial) reached the level of “recommended.” The 39‐item Parkinson's Disease Questionnaire is the most thoroughly tested and applied questionnaire. Three other generic measures (Quality of Life Questionnaire 15D, Schedule for the Evaluation of Individual Quality of Life‐Direct Weighting, and World Health Organization Quality of Life Assessment Short Version) and the specific Parkinson's Disease Quality of Life Scale are “suggested.” With a little additional effort in completing the stipulated requirements, they could reach the “recommended” level. At present there is a wide variety of health‐related quality of life measures for application in the Parkinson's disease setting, and the task force does not recommend the development of a new scale. Selection of the most appropriate instrument for a particular objective requires consideration of the characteristics of each scale and the goals of the assessment. © 2011 Movement Disorder Society
Url:
DOI: 10.1002/mds.23834
Links to Exploration step
ISTEX:C01E2DAFFA05A560AE15850ABA73BB5C7BBF6942Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Health‐related quality‐of‐life scales in Parkinson's disease: Critique and recommendations</title><author><name sortKey="Martinez Artin, Pablo" sort="Martinez Artin, Pablo" uniqKey="Martinez Artin P" first="Pablo" last="Martinez-Martin">Pablo Martinez-Martin</name><affiliation><mods:affiliation>Alzheimer Disease Research Unit, CIEN Foundation–Reina Sofia Foundation, Alzheimer Center Reina Sofia Foundation, Carlos III Institute of Health, Madrid, Spain</mods:affiliation></affiliation><affiliation><mods:affiliation>National Center of Epidemiology and CIBERNED, Carlos III Institute of Health, Madrid, Spain</mods:affiliation></affiliation></author><author><name sortKey="Jeukens Isser, Martine" sort="Jeukens Isser, Martine" uniqKey="Jeukens Isser M" first="Martine" last="Jeukens-Visser">Martine Jeukens-Visser</name><affiliation><mods:affiliation>Department of Rehabilitation, Academic Medical Center, Amsterdam, The Netherlands</mods:affiliation></affiliation></author><author><name sortKey="Lyons, Kelly E" sort="Lyons, Kelly E" uniqKey="Lyons K" first="Kelly E." last="Lyons">Kelly E. Lyons</name><affiliation><mods:affiliation>University of Kansas Medical Center, Parkinson's Disease and Movement Disorder Center, Kansas City, Kansas, USA</mods:affiliation></affiliation></author><author><name sortKey="Rodriguez Lazquez, C" sort="Rodriguez Lazquez, C" uniqKey="Rodriguez Lazquez C" first="C." last="Rodriguez-Blazquez">C. Rodriguez-Blazquez</name><affiliation><mods:affiliation>National Center of Epidemiology and CIBERNED, Carlos III Institute of Health, Madrid, Spain</mods:affiliation></affiliation></author><author><name sortKey="Selai, Caroline" sort="Selai, Caroline" uniqKey="Selai C" first="Caroline" last="Selai">Caroline Selai</name><affiliation><mods:affiliation>Sobell Department of Motor Neuroscience & Movement Disorders, University College London, Institute of Neurology, National Hospital for Neurology and Neurosurgery, Queen Square, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Siderowf, Andrew" sort="Siderowf, Andrew" uniqKey="Siderowf A" first="Andrew" last="Siderowf">Andrew Siderowf</name><affiliation><mods:affiliation>Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA</mods:affiliation></affiliation></author><author><name sortKey="Welsh, Mickie" sort="Welsh, Mickie" uniqKey="Welsh M" first="Mickie" last="Welsh">Mickie Welsh</name><affiliation><mods:affiliation>Division of Movement Disorders, USC/Keck School of Medicine, University of Southern California, Los Angeles, California, USA</mods:affiliation></affiliation></author><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation><mods:affiliation>Department of Neurology, University Hospital, Innsbruck, Austria</mods:affiliation></affiliation></author><author><name sortKey="Rascol, Oliver" sort="Rascol, Oliver" uniqKey="Rascol O" first="Oliver" last="Rascol">Oliver Rascol</name><affiliation><mods:affiliation>Laboratoire de Pharmacologie Medicale et Clinique, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name><affiliation><mods:affiliation>Laboratory of Clinical Pharmacology and Therapeutics, Lisbon School of Medicine, Lisbon, Portugal</mods:affiliation></affiliation></author><author><name sortKey="Stebbins, Glenn T" sort="Stebbins, Glenn T" uniqKey="Stebbins G" first="Glenn T." last="Stebbins">Glenn T. Stebbins</name><affiliation><mods:affiliation>Department of Neurological Services, Rush University Medical Center, Chicago, Illinois, USA</mods:affiliation></affiliation></author><author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name><affiliation><mods:affiliation>Department of Neurological Services, Rush University Medical Center, Chicago, Illinois, USA</mods:affiliation></affiliation></author><author><name sortKey="Schrag, Anette" sort="Schrag, Anette" uniqKey="Schrag A" first="Anette" last="Schrag">Anette Schrag</name><affiliation><mods:affiliation>Department of Clinical Neurosciences, Royal Free Hospital, University College London, London, United Kingdom</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:C01E2DAFFA05A560AE15850ABA73BB5C7BBF6942</idno><date when="2011" year="2011">2011</date><idno type="doi">10.1002/mds.23834</idno><idno type="url">https://api.istex.fr/document/C01E2DAFFA05A560AE15850ABA73BB5C7BBF6942/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000264</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Health‐related quality‐of‐life scales in Parkinson's disease: Critique and recommendations</title><author><name sortKey="Martinez Artin, Pablo" sort="Martinez Artin, Pablo" uniqKey="Martinez Artin P" first="Pablo" last="Martinez-Martin">Pablo Martinez-Martin</name><affiliation><mods:affiliation>Alzheimer Disease Research Unit, CIEN Foundation–Reina Sofia Foundation, Alzheimer Center Reina Sofia Foundation, Carlos III Institute of Health, Madrid, Spain</mods:affiliation></affiliation><affiliation><mods:affiliation>National Center of Epidemiology and CIBERNED, Carlos III Institute of Health, Madrid, Spain</mods:affiliation></affiliation></author><author><name sortKey="Jeukens Isser, Martine" sort="Jeukens Isser, Martine" uniqKey="Jeukens Isser M" first="Martine" last="Jeukens-Visser">Martine Jeukens-Visser</name><affiliation><mods:affiliation>Department of Rehabilitation, Academic Medical Center, Amsterdam, The Netherlands</mods:affiliation></affiliation></author><author><name sortKey="Lyons, Kelly E" sort="Lyons, Kelly E" uniqKey="Lyons K" first="Kelly E." last="Lyons">Kelly E. Lyons</name><affiliation><mods:affiliation>University of Kansas Medical Center, Parkinson's Disease and Movement Disorder Center, Kansas City, Kansas, USA</mods:affiliation></affiliation></author><author><name sortKey="Rodriguez Lazquez, C" sort="Rodriguez Lazquez, C" uniqKey="Rodriguez Lazquez C" first="C." last="Rodriguez-Blazquez">C. Rodriguez-Blazquez</name><affiliation><mods:affiliation>National Center of Epidemiology and CIBERNED, Carlos III Institute of Health, Madrid, Spain</mods:affiliation></affiliation></author><author><name sortKey="Selai, Caroline" sort="Selai, Caroline" uniqKey="Selai C" first="Caroline" last="Selai">Caroline Selai</name><affiliation><mods:affiliation>Sobell Department of Motor Neuroscience & Movement Disorders, University College London, Institute of Neurology, National Hospital for Neurology and Neurosurgery, Queen Square, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Siderowf, Andrew" sort="Siderowf, Andrew" uniqKey="Siderowf A" first="Andrew" last="Siderowf">Andrew Siderowf</name><affiliation><mods:affiliation>Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA</mods:affiliation></affiliation></author><author><name sortKey="Welsh, Mickie" sort="Welsh, Mickie" uniqKey="Welsh M" first="Mickie" last="Welsh">Mickie Welsh</name><affiliation><mods:affiliation>Division of Movement Disorders, USC/Keck School of Medicine, University of Southern California, Los Angeles, California, USA</mods:affiliation></affiliation></author><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation><mods:affiliation>Department of Neurology, University Hospital, Innsbruck, Austria</mods:affiliation></affiliation></author><author><name sortKey="Rascol, Oliver" sort="Rascol, Oliver" uniqKey="Rascol O" first="Oliver" last="Rascol">Oliver Rascol</name><affiliation><mods:affiliation>Laboratoire de Pharmacologie Medicale et Clinique, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name><affiliation><mods:affiliation>Laboratory of Clinical Pharmacology and Therapeutics, Lisbon School of Medicine, Lisbon, Portugal</mods:affiliation></affiliation></author><author><name sortKey="Stebbins, Glenn T" sort="Stebbins, Glenn T" uniqKey="Stebbins G" first="Glenn T." last="Stebbins">Glenn T. Stebbins</name><affiliation><mods:affiliation>Department of Neurological Services, Rush University Medical Center, Chicago, Illinois, USA</mods:affiliation></affiliation></author><author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name><affiliation><mods:affiliation>Department of Neurological Services, Rush University Medical Center, Chicago, Illinois, USA</mods:affiliation></affiliation></author><author><name sortKey="Schrag, Anette" sort="Schrag, Anette" uniqKey="Schrag A" first="Anette" last="Schrag">Anette Schrag</name><affiliation><mods:affiliation>Department of Clinical Neurosciences, Royal Free Hospital, University College London, London, United Kingdom</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2011-11">2011-11</date><biblScope unit="volume">26</biblScope><biblScope unit="issue">13</biblScope><biblScope unit="page" from="2371">2371</biblScope><biblScope unit="page" to="2380">2380</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">C01E2DAFFA05A560AE15850ABA73BB5C7BBF6942</idno><idno type="DOI">10.1002/mds.23834</idno><idno type="ArticleID">MDS23834</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>assessment</term><term>health‐related quality of life</term><term>measures</term><term>patient‐reported outcomes</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Health‐related quality of life is an important patient‐reported outcome used in intervention trials and for monitoring the consequences of health status on physical, mental, and social domains. Parkinson's disease is a complex disorder that strongly affects patients' quality of life. Several health‐related quality of life tools have been used in Parkinson's disease. A Movement Disorder Society Task Force was commissioned to rate the psychometric quality of available health‐related quality of life scales as applied to Parkinson's disease. Following the methodology adopted by previous work of the Movement Disorder Society Task Force, a review of generic and specific health‐related quality of life scales applied in studies on Parkinson's disease was completed. Considering the scales from 3 perspectives—use in Parkinson's disease, use by multiple research groups, and clinimetric properties—a final classification as “recommended,” “suggested,” or “listed” was applied to each reviewed instrument. Four generic scales (EuroQoL, Nottingham Health Profile, 36‐Item Short‐Form Health Survey, and Sickness Impact Profile) and 5 specific scales (39‐Item Parkinson's Disease Questionnaire, Parkinson's Disease Questionnaire Short Form, Parkinson's Disease Quality of Life Questionnaire, Parkinson's Impact Scale, and Scales for Outcomes in Parkinson's Disease–Psychosocial) reached the level of “recommended.” The 39‐item Parkinson's Disease Questionnaire is the most thoroughly tested and applied questionnaire. Three other generic measures (Quality of Life Questionnaire 15D, Schedule for the Evaluation of Individual Quality of Life‐Direct Weighting, and World Health Organization Quality of Life Assessment Short Version) and the specific Parkinson's Disease Quality of Life Scale are “suggested.” With a little additional effort in completing the stipulated requirements, they could reach the “recommended” level. At present there is a wide variety of health‐related quality of life measures for application in the Parkinson's disease setting, and the task force does not recommend the development of a new scale. Selection of the most appropriate instrument for a particular objective requires consideration of the characteristics of each scale and the goals of the assessment. © 2011 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Pablo Martinez‐Martin MD, PhD</name><affiliations><json:string>Alzheimer Disease Research Unit, CIEN Foundation–Reina Sofia Foundation, Alzheimer Center Reina Sofia Foundation, Carlos III Institute of Health, Madrid, Spain</json:string><json:string>National Center of Epidemiology and CIBERNED, Carlos III Institute of Health, Madrid, Spain</json:string></affiliations></json:item><json:item><name>Martine Jeukens‐Visser PhD</name><affiliations><json:string>Department of Rehabilitation, Academic Medical Center, Amsterdam, The Netherlands</json:string></affiliations></json:item><json:item><name>Kelly E. Lyons PhD</name><affiliations><json:string>University of Kansas Medical Center, Parkinson's Disease and Movement Disorder Center, Kansas City, Kansas, USA</json:string></affiliations></json:item><json:item><name>C. Rodriguez‐Blazquez BS</name><affiliations><json:string>National Center of Epidemiology and CIBERNED, Carlos III Institute of Health, Madrid, Spain</json:string></affiliations></json:item><json:item><name>Caroline Selai PhD</name><affiliations><json:string>Sobell Department of Motor Neuroscience & Movement Disorders, University College London, Institute of Neurology, National Hospital for Neurology and Neurosurgery, Queen Square, London, United Kingdom</json:string></affiliations></json:item><json:item><name>Andrew Siderowf MD</name><affiliations><json:string>Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA</json:string></affiliations></json:item><json:item><name>Mickie Welsh RN, DNSC</name><affiliations><json:string>Division of Movement Disorders, USC/Keck School of Medicine, University of Southern California, Los Angeles, California, USA</json:string></affiliations></json:item><json:item><name>Werner Poewe MD</name><affiliations><json:string>Department of Neurology, University Hospital, Innsbruck, Austria</json:string></affiliations></json:item><json:item><name>Oliver Rascol MD</name><affiliations><json:string>Laboratoire de Pharmacologie Medicale et Clinique, Toulouse, France</json:string></affiliations></json:item><json:item><name>Cristina Sampaio MD, PhD</name><affiliations><json:string>Laboratory of Clinical Pharmacology and Therapeutics, Lisbon School of Medicine, Lisbon, Portugal</json:string></affiliations></json:item><json:item><name>Glenn T. Stebbins MD</name><affiliations><json:string>Department of Neurological Services, Rush University Medical Center, Chicago, Illinois, USA</json:string></affiliations></json:item><json:item><name>Christopher G. Goetz MD</name><affiliations><json:string>Department of Neurological Services, Rush University Medical Center, Chicago, Illinois, USA</json:string></affiliations></json:item><json:item><name>Anette Schrag FRCP, PhD</name><affiliations><json:string>Department of Clinical Neurosciences, Royal Free Hospital, University College London, London, United Kingdom</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>health‐related quality of life</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>measures</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>assessment</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>patient‐reported outcomes</value></json:item></subject><articleId><json:string>MDS23834</json:string></articleId><language><json:string>eng</json:string></language><abstract>Health‐related quality of life is an important patient‐reported outcome used in intervention trials and for monitoring the consequences of health status on physical, mental, and social domains. Parkinson's disease is a complex disorder that strongly affects patients' quality of life. Several health‐related quality of life tools have been used in Parkinson's disease. A Movement Disorder Society Task Force was commissioned to rate the psychometric quality of available health‐related quality of life scales as applied to Parkinson's disease. Following the methodology adopted by previous work of the Movement Disorder Society Task Force, a review of generic and specific health‐related quality of life scales applied in studies on Parkinson's disease was completed. Considering the scales from 3 perspectives—use in Parkinson's disease, use by multiple research groups, and clinimetric properties—a final classification as “recommended,” “suggested,” or “listed” was applied to each reviewed instrument. Four generic scales (EuroQoL, Nottingham Health Profile, 36‐Item Short‐Form Health Survey, and Sickness Impact Profile) and 5 specific scales (39‐Item Parkinson's Disease Questionnaire, Parkinson's Disease Questionnaire Short Form, Parkinson's Disease Quality of Life Questionnaire, Parkinson's Impact Scale, and Scales for Outcomes in Parkinson's Disease–Psychosocial) reached the level of “recommended.” The 39‐item Parkinson's Disease Questionnaire is the most thoroughly tested and applied questionnaire. Three other generic measures (Quality of Life Questionnaire 15D, Schedule for the Evaluation of Individual Quality of Life‐Direct Weighting, and World Health Organization Quality of Life Assessment Short Version) and the specific Parkinson's Disease Quality of Life Scale are “suggested.” With a little additional effort in completing the stipulated requirements, they could reach the “recommended” level. At present there is a wide variety of health‐related quality of life measures for application in the Parkinson's disease setting, and the task force does not recommend the development of a new scale. Selection of the most appropriate instrument for a particular objective requires consideration of the characteristics of each scale and the goals of the assessment. © 2011 Movement Disorder Society</abstract><qualityIndicators><score>8</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>5</keywordCount><abstractCharCount>2318</abstractCharCount><pdfWordCount>7202</pdfWordCount><pdfCharCount>48070</pdfCharCount><pdfPageCount>10</pdfPageCount><abstractWordCount>320</abstractWordCount></qualityIndicators><title>Health‐related quality‐of‐life scales in Parkinson's disease: Critique and recommendations</title><genre><json:string>article</json:string></genre><host><volume>26</volume><publisherId><json:string>MDS</json:string></publisherId><pages><total>10</total><last>2380</last><first>2371</first></pages><issn><json:string>0885-3185</json:string></issn><issue>13</issue><subject><json:item><value>Research Article</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8257</json:string></eissn><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2011</publicationDate><copyrightDate>2011</copyrightDate><doi><json:string>10.1002/mds.23834</json:string></doi><id>C01E2DAFFA05A560AE15850ABA73BB5C7BBF6942</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/C01E2DAFFA05A560AE15850ABA73BB5C7BBF6942/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/C01E2DAFFA05A560AE15850ABA73BB5C7BBF6942/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/C01E2DAFFA05A560AE15850ABA73BB5C7BBF6942/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Health‐related quality‐of‐life scales in Parkinson's disease: Critique and recommendations</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>WILEY</p></availability><date>2011</date></publicationStmt><notesStmt><note type="content">*Relevant conflicts of interest/financial disclosures: Nothing to report.</note><note type="content">*Full financial disclosures and author roles may be found in the online version of this article.</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Health‐related quality‐of‐life scales in Parkinson's disease: Critique and recommendations</title><author><persName><forename type="first">Pablo</forename><surname>Martinez‐Martin</surname></persName><roleName type="degree">MD, PhD</roleName><note type="correspondence"><p>Correspondence: National Centre of Epidemiology, Carlos III Institute of Health, Av. Monforte de Lemos, 5, 28029 Madrid, Spain</p></note><affiliation>Alzheimer Disease Research Unit, CIEN Foundation–Reina Sofia Foundation, Alzheimer Center Reina Sofia Foundation, Carlos III Institute of Health, Madrid, Spain</affiliation><affiliation>National Center of Epidemiology and CIBERNED, Carlos III Institute of Health, Madrid, Spain</affiliation></author><author><persName><forename type="first">Martine</forename><surname>Jeukens‐Visser</surname></persName><roleName type="degree">PhD</roleName><affiliation>Department of Rehabilitation, Academic Medical Center, Amsterdam, The Netherlands</affiliation></author><author><persName><forename type="first">Kelly E.</forename><surname>Lyons</surname></persName><roleName type="degree">PhD</roleName><affiliation>University of Kansas Medical Center, Parkinson's Disease and Movement Disorder Center, Kansas City, Kansas, USA</affiliation></author><author><persName><forename type="first">C.</forename><surname>Rodriguez‐Blazquez</surname></persName><roleName type="degree">BS</roleName><affiliation>National Center of Epidemiology and CIBERNED, Carlos III Institute of Health, Madrid, Spain</affiliation></author><author><persName><forename type="first">Caroline</forename><surname>Selai</surname></persName><roleName type="degree">PhD</roleName><affiliation>Sobell Department of Motor Neuroscience & Movement Disorders, University College London, Institute of Neurology, National Hospital for Neurology and Neurosurgery, Queen Square, London, United Kingdom</affiliation></author><author><persName><forename type="first">Andrew</forename><surname>Siderowf</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA</affiliation></author><author><persName><forename type="first">Mickie</forename><surname>Welsh</surname></persName><roleName type="degree">RN, DNSC</roleName><affiliation>Division of Movement Disorders, USC/Keck School of Medicine, University of Southern California, Los Angeles, California, USA</affiliation></author><author><persName><forename type="first">Werner</forename><surname>Poewe</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, University Hospital, Innsbruck, Austria</affiliation></author><author><persName><forename type="first">Oliver</forename><surname>Rascol</surname></persName><roleName type="degree">MD</roleName><affiliation>Laboratoire de Pharmacologie Medicale et Clinique, Toulouse, France</affiliation></author><author><persName><forename type="first">Cristina</forename><surname>Sampaio</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>Laboratory of Clinical Pharmacology and Therapeutics, Lisbon School of Medicine, Lisbon, Portugal</affiliation></author><author><persName><forename type="first">Glenn T.</forename><surname>Stebbins</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurological Services, Rush University Medical Center, Chicago, Illinois, USA</affiliation></author><author><persName><forename type="first">Christopher G.</forename><surname>Goetz</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurological Services, Rush University Medical Center, Chicago, Illinois, USA</affiliation></author><author><persName><forename type="first">Anette</forename><surname>Schrag</surname></persName><roleName type="degree">FRCP, PhD</roleName><affiliation>Department of Clinical Neurosciences, Royal Free Hospital, University College London, London, United Kingdom</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2011-11"></date><biblScope unit="volume">26</biblScope><biblScope unit="issue">13</biblScope><biblScope unit="page" from="2371">2371</biblScope><biblScope unit="page" to="2380">2380</biblScope></imprint></monogr><idno type="istex">C01E2DAFFA05A560AE15850ABA73BB5C7BBF6942</idno><idno type="DOI">10.1002/mds.23834</idno><idno type="ArticleID">MDS23834</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2011</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Health‐related quality of life is an important patient‐reported outcome used in intervention trials and for monitoring the consequences of health status on physical, mental, and social domains. Parkinson's disease is a complex disorder that strongly affects patients' quality of life. Several health‐related quality of life tools have been used in Parkinson's disease. A Movement Disorder Society Task Force was commissioned to rate the psychometric quality of available health‐related quality of life scales as applied to Parkinson's disease. Following the methodology adopted by previous work of the Movement Disorder Society Task Force, a review of generic and specific health‐related quality of life scales applied in studies on Parkinson's disease was completed. Considering the scales from 3 perspectives—use in Parkinson's disease, use by multiple research groups, and clinimetric properties—a final classification as “recommended,” “suggested,” or “listed” was applied to each reviewed instrument. Four generic scales (EuroQoL, Nottingham Health Profile, 36‐Item Short‐Form Health Survey, and Sickness Impact Profile) and 5 specific scales (39‐Item Parkinson's Disease Questionnaire, Parkinson's Disease Questionnaire Short Form, Parkinson's Disease Quality of Life Questionnaire, Parkinson's Impact Scale, and Scales for Outcomes in Parkinson's Disease–Psychosocial) reached the level of “recommended.” The 39‐item Parkinson's Disease Questionnaire is the most thoroughly tested and applied questionnaire. Three other generic measures (Quality of Life Questionnaire 15D, Schedule for the Evaluation of Individual Quality of Life‐Direct Weighting, and World Health Organization Quality of Life Assessment Short Version) and the specific Parkinson's Disease Quality of Life Scale are “suggested.” With a little additional effort in completing the stipulated requirements, they could reach the “recommended” level. At present there is a wide variety of health‐related quality of life measures for application in the Parkinson's disease setting, and the task force does not recommend the development of a new scale. Selection of the most appropriate instrument for a particular objective requires consideration of the characteristics of each scale and the goals of the assessment. © 2011 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Parkinson's disease</term></item><item><term>health‐related quality of life</term></item><item><term>measures</term></item><item><term>assessment</term></item><item><term>patient‐reported outcomes</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Research Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2010-02-17">Received</change><change when="2011-05-02">Registration</change><change when="2011-11">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/C01E2DAFFA05A560AE15850ABA73BB5C7BBF6942/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="130"><doi origin="wiley" registered="yes">10.1002/mds.v26.13</doi><numberingGroup><numbering type="journalVolume" number="26">26</numbering><numbering type="journalIssue">13</numbering></numberingGroup><coverDate startDate="2011-11">November 2011</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="120" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.23834</doi><idGroup><id type="unit" value="MDS23834"></id></idGroup><countGroup><count type="pageTotal" number="10"></count></countGroup><titleGroup><title type="articleCategory">Research Article</title><title type="tocHeading1">Research Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 2011 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2010-02-17"></event><event type="manuscriptRevised" date="2011-04-28"></event><event type="manuscriptAccepted" date="2011-05-02"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:3.0.1 mode:FullText" date="2011-12-13"></event><event type="publishedOnlineEarlyUnpaginated" date="2011-07-06"></event><event type="publishedOnlineFinalForm" date="2011-11-22"></event><event type="firstOnline" date="2011-07-06"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">2371</numbering><numbering type="pageLast">2380</numbering></numberingGroup><correspondenceTo>National Centre of Epidemiology, Carlos III Institute of Health, Av. Monforte de Lemos, 5, 28029 Madrid, Spain</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS23834.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="2"></count><count type="referenceTotal" number="131"></count><count type="wordTotal" number="10006"></count></countGroup><titleGroup><title type="main" xml:lang="en">Health‐related quality‐of‐life scales in Parkinson's disease: Critique and recommendations<link href="#fn1"></link><link href="#fn2"></link></title><title type="short" xml:lang="en">Health‐Related QoL Scales in PD</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1 #af2" corresponding="yes"><personName><givenNames>Pablo</givenNames><familyName>Martinez‐Martin</familyName><degrees>MD, PhD</degrees></personName><contactDetails><email>pmartinez@isciii.es</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Martine</givenNames><familyName>Jeukens‐Visser</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af4"><personName><givenNames>Kelly E.</givenNames><familyName>Lyons</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af2"><personName><givenNames>C.</givenNames><familyName>Rodriguez‐Blazquez</familyName><degrees>BS</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af5"><personName><givenNames>Caroline</givenNames><familyName>Selai</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af6"><personName><givenNames>Andrew</givenNames><familyName>Siderowf</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au7" creatorRole="author" affiliationRef="#af7"><personName><givenNames>Mickie</givenNames><familyName>Welsh</familyName><degrees>RN, DNSC</degrees></personName></creator><creator xml:id="au8" creatorRole="author" affiliationRef="#af8"><personName><givenNames>Werner</givenNames><familyName>Poewe</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au9" creatorRole="author" affiliationRef="#af9"><personName><givenNames>Oliver</givenNames><familyName>Rascol</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au10" creatorRole="author" affiliationRef="#af10"><personName><givenNames>Cristina</givenNames><familyName>Sampaio</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au11" creatorRole="author" affiliationRef="#af11"><personName><givenNames>Glenn T.</givenNames><familyName>Stebbins</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au12" creatorRole="author" affiliationRef="#af11"><personName><givenNames>Christopher G.</givenNames><familyName>Goetz</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au13" creatorRole="author" affiliationRef="#af12"><personName><givenNames>Anette</givenNames><familyName>Schrag</familyName><degrees>FRCP, PhD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="ES" type="organization"><unparsedAffiliation>Alzheimer Disease Research Unit, CIEN Foundation–Reina Sofia Foundation, Alzheimer Center Reina Sofia Foundation, Carlos III Institute of Health, Madrid, Spain</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="ES" type="organization"><unparsedAffiliation>National Center of Epidemiology and CIBERNED, Carlos III Institute of Health, Madrid, Spain</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="NL" type="organization"><unparsedAffiliation>Department of Rehabilitation, Academic Medical Center, Amsterdam, The Netherlands</unparsedAffiliation></affiliation><affiliation xml:id="af4" countryCode="US" type="organization"><unparsedAffiliation>University of Kansas Medical Center, Parkinson's Disease and Movement Disorder Center, Kansas City, Kansas, USA</unparsedAffiliation></affiliation><affiliation xml:id="af5" countryCode="GB" type="organization"><unparsedAffiliation>Sobell Department of Motor Neuroscience & Movement Disorders, University College London, Institute of Neurology, National Hospital for Neurology and Neurosurgery, Queen Square, London, United Kingdom</unparsedAffiliation></affiliation><affiliation xml:id="af6" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA</unparsedAffiliation></affiliation><affiliation xml:id="af7" countryCode="US" type="organization"><unparsedAffiliation>Division of Movement Disorders, USC/Keck School of Medicine, University of Southern California, Los Angeles, California, USA</unparsedAffiliation></affiliation><affiliation xml:id="af8" countryCode="AT" type="organization"><unparsedAffiliation>Department of Neurology, University Hospital, Innsbruck, Austria</unparsedAffiliation></affiliation><affiliation xml:id="af9" countryCode="FR" type="organization"><unparsedAffiliation>Laboratoire de Pharmacologie Medicale et Clinique, Toulouse, France</unparsedAffiliation></affiliation><affiliation xml:id="af10" countryCode="PT" type="organization"><unparsedAffiliation>Laboratory of Clinical Pharmacology and Therapeutics, Lisbon School of Medicine, Lisbon, Portugal</unparsedAffiliation></affiliation><affiliation xml:id="af11" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurological Services, Rush University Medical Center, Chicago, Illinois, USA</unparsedAffiliation></affiliation><affiliation xml:id="af12" countryCode="GB" type="organization"><unparsedAffiliation>Department of Clinical Neurosciences, Royal Free Hospital, University College London, London, United Kingdom</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Parkinson's disease</keyword><keyword xml:id="kwd2">health‐related quality of life</keyword><keyword xml:id="kwd3">measures</keyword><keyword xml:id="kwd4">assessment</keyword><keyword xml:id="kwd5">patient‐reported outcomes</keyword></keywordGroup><supportingInformation><p> Additional Supporting Information may be found in the online version of this article. </p><supportingInfoItem><mediaResource alt="supporting information" href="urn-x:wiley:08853185:media:mds23834:MDS_23834_sm_suppinfo"></mediaResource><caption>Supporting Information.</caption></supportingInfoItem></supportingInformation><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Health‐related quality of life is an important patient‐reported outcome used in intervention trials and for monitoring the consequences of health status on physical, mental, and social domains. Parkinson's disease is a complex disorder that strongly affects patients' quality of life. Several health‐related quality of life tools have been used in Parkinson's disease. A Movement Disorder Society Task Force was commissioned to rate the psychometric quality of available health‐related quality of life scales as applied to Parkinson's disease. Following the methodology adopted by previous work of the Movement Disorder Society Task Force, a review of generic and specific health‐related quality of life scales applied in studies on Parkinson's disease was completed. Considering the scales from 3 perspectives—use in Parkinson's disease, use by multiple research groups, and clinimetric properties—a final classification as “recommended,” “suggested,” or “listed” was applied to each reviewed instrument. Four generic scales (EuroQoL, Nottingham Health Profile, 36‐Item Short‐Form Health Survey, and Sickness Impact Profile) and 5 specific scales (39‐Item Parkinson's Disease Questionnaire, Parkinson's Disease Questionnaire Short Form, Parkinson's Disease Quality of Life Questionnaire, Parkinson's Impact Scale, and Scales for Outcomes in Parkinson's Disease–Psychosocial) reached the level of “recommended.” The 39‐item Parkinson's Disease Questionnaire is the most thoroughly tested and applied questionnaire. Three other generic measures (Quality of Life Questionnaire 15D, Schedule for the Evaluation of Individual Quality of Life‐Direct Weighting, and World Health Organization Quality of Life Assessment Short Version) and the specific Parkinson's Disease Quality of Life Scale are “suggested.” With a little additional effort in completing the stipulated requirements, they could reach the “recommended” level. At present there is a wide variety of health‐related quality of life measures for application in the Parkinson's disease setting, and the task force does not recommend the development of a new scale. Selection of the most appropriate instrument for a particular objective requires consideration of the characteristics of each scale and the goals of the assessment. © 2011 <i>Movement</i> Disorder Society</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn1"><p><b>Relevant conflicts of interest/financial disclosures:</b> Nothing to report.</p></note><note xml:id="fn2"><p>Full financial disclosures and author roles may be found in the online version of this article.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Health‐related quality‐of‐life scales in Parkinson's disease: Critique and recommendations</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Health‐Related QoL Scales in PD</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Health‐related quality‐of‐life scales in Parkinson's disease: Critique and recommendations</title></titleInfo><name type="personal"><namePart type="given">Pablo</namePart><namePart type="family">Martinez‐Martin</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Alzheimer Disease Research Unit, CIEN Foundation–Reina Sofia Foundation, Alzheimer Center Reina Sofia Foundation, Carlos III Institute of Health, Madrid, Spain</affiliation><affiliation>National Center of Epidemiology and CIBERNED, Carlos III Institute of Health, Madrid, Spain</affiliation><description>Correspondence: National Centre of Epidemiology, Carlos III Institute of Health, Av. Monforte de Lemos, 5, 28029 Madrid, Spain</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Martine</namePart><namePart type="family">Jeukens‐Visser</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Department of Rehabilitation, Academic Medical Center, Amsterdam, The Netherlands</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Kelly E.</namePart><namePart type="family">Lyons</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>University of Kansas Medical Center, Parkinson's Disease and Movement Disorder Center, Kansas City, Kansas, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C.</namePart><namePart type="family">Rodriguez‐Blazquez</namePart><namePart type="termsOfAddress">BS</namePart><affiliation>National Center of Epidemiology and CIBERNED, Carlos III Institute of Health, Madrid, Spain</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Caroline</namePart><namePart type="family">Selai</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Sobell Department of Motor Neuroscience & Movement Disorders, University College London, Institute of Neurology, National Hospital for Neurology and Neurosurgery, Queen Square, London, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Andrew</namePart><namePart type="family">Siderowf</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Mickie</namePart><namePart type="family">Welsh</namePart><namePart type="termsOfAddress">RN, DNSC</namePart><affiliation>Division of Movement Disorders, USC/Keck School of Medicine, University of Southern California, Los Angeles, California, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Werner</namePart><namePart type="family">Poewe</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, University Hospital, Innsbruck, Austria</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Oliver</namePart><namePart type="family">Rascol</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Laboratoire de Pharmacologie Medicale et Clinique, Toulouse, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Cristina</namePart><namePart type="family">Sampaio</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Laboratory of Clinical Pharmacology and Therapeutics, Lisbon School of Medicine, Lisbon, Portugal</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Glenn T.</namePart><namePart type="family">Stebbins</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurological Services, Rush University Medical Center, Chicago, Illinois, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Christopher G.</namePart><namePart type="family">Goetz</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurological Services, Rush University Medical Center, Chicago, Illinois, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Anette</namePart><namePart type="family">Schrag</namePart><namePart type="termsOfAddress">FRCP, PhD</namePart><affiliation>Department of Clinical Neurosciences, Royal Free Hospital, University College London, London, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2011-11</dateIssued><dateCaptured encoding="w3cdtf">2010-02-17</dateCaptured><dateValid encoding="w3cdtf">2011-05-02</dateValid><copyrightDate encoding="w3cdtf">2011</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="tables">2</extent><extent unit="references">131</extent><extent unit="words">10006</extent></physicalDescription><abstract lang="en">Health‐related quality of life is an important patient‐reported outcome used in intervention trials and for monitoring the consequences of health status on physical, mental, and social domains. Parkinson's disease is a complex disorder that strongly affects patients' quality of life. Several health‐related quality of life tools have been used in Parkinson's disease. A Movement Disorder Society Task Force was commissioned to rate the psychometric quality of available health‐related quality of life scales as applied to Parkinson's disease. Following the methodology adopted by previous work of the Movement Disorder Society Task Force, a review of generic and specific health‐related quality of life scales applied in studies on Parkinson's disease was completed. Considering the scales from 3 perspectives—use in Parkinson's disease, use by multiple research groups, and clinimetric properties—a final classification as “recommended,” “suggested,” or “listed” was applied to each reviewed instrument. Four generic scales (EuroQoL, Nottingham Health Profile, 36‐Item Short‐Form Health Survey, and Sickness Impact Profile) and 5 specific scales (39‐Item Parkinson's Disease Questionnaire, Parkinson's Disease Questionnaire Short Form, Parkinson's Disease Quality of Life Questionnaire, Parkinson's Impact Scale, and Scales for Outcomes in Parkinson's Disease–Psychosocial) reached the level of “recommended.” The 39‐item Parkinson's Disease Questionnaire is the most thoroughly tested and applied questionnaire. Three other generic measures (Quality of Life Questionnaire 15D, Schedule for the Evaluation of Individual Quality of Life‐Direct Weighting, and World Health Organization Quality of Life Assessment Short Version) and the specific Parkinson's Disease Quality of Life Scale are “suggested.” With a little additional effort in completing the stipulated requirements, they could reach the “recommended” level. At present there is a wide variety of health‐related quality of life measures for application in the Parkinson's disease setting, and the task force does not recommend the development of a new scale. Selection of the most appropriate instrument for a particular objective requires consideration of the characteristics of each scale and the goals of the assessment. © 2011 Movement Disorder Society</abstract><note type="content">*Relevant conflicts of interest/financial disclosures: Nothing to report.</note><note type="content">*Full financial disclosures and author roles may be found in the online version of this article.</note><subject lang="en"><genre>Keywords</genre><topic>Parkinson's disease</topic><topic>health‐related quality of life</topic><topic>measures</topic><topic>assessment</topic><topic>patient‐reported outcomes</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><genre type="Journal">journal</genre><note type="content"> Additional Supporting Information may be found in the online version of this article.Supporting Info Item: Supporting Information. - </note><subject><genre>article category</genre><topic>Research Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><detail type="issue"><caption>no.</caption><number>13</number></detail><extent unit="pages"><start>2371</start><end>2380</end><total>10</total></extent></part></relatedItem><identifier type="istex">C01E2DAFFA05A560AE15850ABA73BB5C7BBF6942</identifier><identifier type="DOI">10.1002/mds.23834</identifier><identifier type="ArticleID">MDS23834</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2011 Movement Disorder Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000264 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000264 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:C01E2DAFFA05A560AE15850ABA73BB5C7BBF6942
|texte= Health‐related quality‐of‐life scales in Parkinson's disease: Critique and recommendations
}}
| This area was generated with Dilib version V0.6.23. |  |